Intercept Pharmaceuticals, Inc. (ICPT)
(Delayed Data from NSDQ)
$89.92 USD
+1.71 (1.94%)
Updated May 3, 2019 04:00 PM ET
After-Market: $89.98 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMEarnings News For ICPT
-
Intercept: Q3 Earnings Snapshot
-
Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know
-
Why Is Intercept (ICPT) Up 0.6% Since Last Earnings Report?
-
Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y
-
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates
-
Intercept: Q2 Earnings Snapshot
-
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
-
Intercept Pharmaceuticals (ICPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Intercept (ICPT) Gains 26.2% YTD: What's in Store?
-
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y
-
Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates
-
Intercept: Q1 Earnings Snapshot
-
Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
-
Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase
-
Intercept: Q4 Earnings Snapshot
-
Intercept: Q4 Earnings Snapshot
-
Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates
-
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance
-
Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
-
Why Is Intercept (ICPT) Down 3.9% Since Last Earnings Report?
-
Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised
-
Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates
-
Intercept: Q3 Earnings Snapshot
-
Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update